Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of BAY 3547926 (actinium-225 labeled anti-GPC3 antibody conjugate) alone and in combination in advanced hepatocellular carcinoma
jRCT2031260213Phase 1Recruiting
- Sponsor
- Bayer
- Start
- Jun 2026
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 1, open-label trial of BAY 3547926 in hepatocellular carcinoma (HCC) (2 arms), sponsored by Bayer. Started Jun 2026; status: recruiting.
02
Drugs
BAY 3547926
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT2031260213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260213.